Top Markets
#1 NKN NKN +160.00%
#2 Bluwhale Bluwhale +34.89%
#3 Codatta Codatta +30.46%
#4 SAFEcoin SAFEcoin +28.54%
#5 Saakuru Saakuru +24.27%
#6 StakeStone StakeStone +19.16%
#7 Particle Network Particle Network +18.79%
#8 Yooldo Games Yooldo Games +15.38%
#9 Arcblock Arcblock +14.06%
#10 Ski Mask Dog Ski Mask Dog +13.94%
Coin of the day
NKN NKN
Setări
Limbă
ROMâNă
Monedă
USD
Temă
Intellipharmaceutics International Inc. Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc.

IPCIF
Rang în acțiuni #99999
Intellipharmaceutics International Inc., a pharmaceutical company, researches,... Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.
Preț acțiune
$0.15
Capitalizare de piață
$4.96M
Schimbare (1 zi)
0.00%
Schimbare (1 an)
0.00%
Țară
CA
Tranzacționează Intellipharmaceutics International Inc. (IPCIF)

Categorie

Healthcare
Venituri pentru Intellipharmaceutics International Inc. (IPCIF)
Venituri în Aug 2023 TTM: $904.95K
Conform celor mai recente rapoarte financiare ale Intellipharmaceutics International Inc., venitul actual al companiei (TTM) este $904.95K. În anul 2021, compania a avut un venit de $65.73K o scădere comparativ cu venitul din anul 2020, care a fost de $1.40M. Venitul reprezintă suma totală generată de o companie din vânzarea de bunuri sau servicii. Spre deosebire de profit, cheltuielile nu sunt scăzute.
Istoricul veniturilor pentru Intellipharmaceutics International Inc. din 1999 până în 2026
Venituri la sfârșitul fiecărui an
An Venituri Schimbă
2026 (TTM) $904.95K 1,276.80%
2022 $65.73K 0.00%
2021 $65.73K -95.31%
2020 $1.40M 0.00%
2019 $1.40M -18.17%
2018 $1.71M -68.88%
2017 $5.50M 144.97%
2016 $2.25M -45.11%
2015 $4.09M -53.32%
2014 $8.77M 474.13%
2013 $1.53M 1,326.33%
2012 $107.09K -78.66%
2011 $501.81K -65.61%
2010 $1.46M 0.00%
2008 0.00 0.00%
2007 0.00 0.00%
2006 0.00 0.00%
2005 0.00 0.00%
2004 0.00 0.00%
2003 0.00 0.00%
2002 0.00 -100.00%
2001 $1.00K 0.02%
2000 $999.82 -99.00%
1999 $100.06K 0.00%
Venituri pentru companii similare sau concurente
Companie Venituri Diferență de venituri Țara
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $48.44B 5,352,315.73%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.04B 1,330,189.32%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.34B 1,584,845.40%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B 1,003,525.57%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $5.49B 606,708.00%
NL